Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vistry shares slide as profits slump, divi axed after 'disappointing' year

(Sharecast News) - House builder Vistry reported a slump in profits after "disappointing" year amid challenging market conditions, abandoned projects and cost overruns that forced it to suspend its dividend. Pre-tax profit for 2024 fell 64% to £105.5m despite a 7% rise in completions. Vistry added that its forward order book totalled £4.4bn in the year to date, compared with £4.6bn last year, while the group sales rate was down to 0.59 per site per week from 0.81, reflecting a low volume of partner-funded transactions in the first quarter.

The company, which pivoted to building affordable homes in partnership with local authorities and housing associations, issued three profit warnings in the last quarter of the year and halved its operating divisions to three as a result of its problems.

On an adjusted basis profits fell by 35% to £263.5m. Completions done in partnership with housing associations rose 18% to 12,633, while homes sold on the open market were down 15% to 4,592.

"Following the government's recent announcement of an additional £2bn of affordable housing funding to the existing affordable homes programme, we expect partner funded activity to step-up during the year, resulting in a greater H2 weighting of delivery for the group in 2025," the company said on Wednesday.

"Overall, we are expecting our partner funded volumes in 2025 to be at a similar level to 2024, with strong momentum going into 2026."

The government this week said it would fund 18,000 affordable and social homes, as part of the target to build 1.5 million houses over the course of the current parliament.

Vistry, formerly Bovis Homes, said it had seen "some uptick" in open market sales in the past four weeks and expected this to continue to improve.

The company was rocked by an accounting scandal last year when it emerged that cost overruns on building projects were bigger than previously estimated. This resulted in Vistry taking a £165m hit on its 2024 accounts, which cut profit by £91.5m with the remainder affecting future years.

"With profits falling and debt levels rising, it looks like Vistry's getting nervous and in a bid to shore up the balance sheet, this year's final dividend has been halted. Further dividend payments will be subject to improved financial performance, with an uplift in cash generation and lowering debt levels seen as higher priorities for now," said Hargreaves Lansdown analyst Aarin Chiekrie.

"2025 hasn't got off to the best of starts either, with sales rates down significantly year-to-date as partner-funded transactions have pulled back. "

He added that the new government proposals offered "a glimmer of respite from the bad news".

"This aligns well with Vistry's strategy, which focuses on increasing volumes of affordable housing for UK buyers. Performance is expected to improve as the year progresses, but given its recent series of missteps, management will have to start delivering more good news if they want to rebuild investors' confidence."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.